NEW YORK (GenomeWeb) – Cantor Fitzgerald yesterday initiated coverage of Thermo Fisher Scientific with a rating of Overweight and a price target of $194 per share.

In a note to investors, Cantor analyst Bryan Brokmeier said that as the largest company in the highly-fragmented life science tools and diagnostics sector, Thermo Fisher has "significant opportunity for organic growth at the expense of weaker competitors," adding that the company is "well-positioned to benefit from positive secular trends, as well as capture share given its position in attractive end markets."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.